{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T03:10:38Z","timestamp":1648609838474},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","funder":[{"name":"Cubist Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40121-015-0094-6","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T08:32:51Z","timestamp":1445329971000},"page":"513-518","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining Extended Spectrum \u03b2-Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing"],"prefix":"10.1007","volume":"4","author":[{"given":"Christina A.","family":"Sutherland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared L.","family":"Crandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"issue":"3","key":"94_CR1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969\u201376.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"94_CR2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14656566.2015.993381","volume":"16","author":"AK Thabit","year":"2015","unstructured":"Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159\u201377.","journal-title":"Expert Opin Pharmacother"},{"key":"94_CR3","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24 U. Wayne: Clinical and Laboratory Standards Institute; 2014."},{"key":"94_CR4","unstructured":"European Committee on Antimicrobial Susceptibility Testing. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Version 1; 2013."},{"issue":"9","key":"94_CR5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/cid\/cit017","volume":"56","author":"MN Dudley","year":"2013","unstructured":"Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN, Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis. 2013;56(9):1301\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"94_CR6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/JCM.00219-10","volume":"48","author":"Kenneth Thomas","year":"2010","unstructured":"Thomas Kenneth. Extended-spectrum-\u03b2-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol. 2010;48(4):1019\u201325.","journal-title":"J Clin Microbiol"},{"key":"94_CR7","unstructured":"Cubist Pharmaceuticals. Zebraxa-US prescribing information. Lexington: Cubist Pharmaceuticals; 2015."},{"key":"94_CR8","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document M07-A9. Wayne: Clinical and Laboratory Standards Institute; 2012."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-015-0094-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:37:10Z","timestamp":1498253830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-015-0094-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1007\/s40121-015-0094-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}